Prevalence of Pathogenic Antibodies in Psychosis (PPiP)2 study


The PPiP study aims to understand the prevalence of pathogenic antibodies in patients with symptoms of psychosis.



The immune system normally controls our ability to fight infection. If the immune system goes wrong it may attack our own body, causing diseases called ‘autoimmune’ diseases. It has been discovered that some of these autoimmune disease can affect the brain, and in the early stages of the disease they can manifest through symptoms of psychosis.

We can diagnose some of these autoimmune diseases using blood tests. We are specifically interested in antibodies that may be the cause of symptoms of psychosis and possibly of some cases of schizophrenia.

We are working with Mental Health services across England to estimate the prevalence of these autoimmune diseases in people with psychosis.



The PPiP2 study includes participants from mental health services between 18-70 years of age who are experiencing their first episode of psychosis or relapse of psychosis symptoms (there needs to be a period of at least 6 months of remission prior to the current episode).

PPiP2 includes patients from over 30 sites across England and will

continue to recruit patients until the end of August 2020.



If you, or someone you care for, is interested to take part in the PPiP2 study, you can find more information here.

map_ppip sites_uk


Social Media

You can keep up to date with the PPiP2 study by following us on social media

PPiP2 sites distribution - for the full list check the "Get Involved" tab on the top menu

Twitter square blue large Facebook square blue large

This study is funded by the MRC.